PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT), a clinical-stage biotechnology company focused on developing cutting-edge immunotherapies designed to revolutionize cancer treatment, has announced a significant public offering. The company is issuing a total of 3,066,666 units in an underwritten public offering, which includes an additional 399,999 units made available due to the full exercise of the underwriter's option to purchase more units. This strategic decision is aimed at bolstering the companys financial foundation for ongoing and future projects.

Each of the units offered consists of one common share, or a pre-funded warrant (known as a Pre-Funded Warrant) in lieu of the common share, paired with a warrant (referred to as the Warrants). These units are being sold to the public at an attractive price of $4.50 per unit. This pricing is inclusive of the exercise price for the Pre-Funded Warrants, with the total gross proceeds expected to reach approximately $13.8 million, prior to the deduction of underwriting discounts and other offering expenses.

In an encouraging development for investors, the included Warrants have received approval for listing on the Nasdaq Capital Market. They are anticipated to begin trading under the symbol BCTXZ starting April 25, 2025. Each Warrant is designed to be immediately exercisable and will allow the holder to purchase one common share at an exercise price of $5.25 per share. These Warrants will remain valid for five years from the date of issuance, offering potential future value to investors.

The closing of this public offering is anticipated to take place on April 28, 2025, assuming that all customary closing conditions are met. In a noteworthy procedural move, BriaCell is leveraging an exemption outlined in Section 602.1 of the TSX Company Manual. This regulation stipulates that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers listed on recognized exchanges, such as Nasdaq, allowing for this streamlined process.

BriaCell plans to allocate the net proceeds from this offering for various purposes, including covering working capital expenses, supporting general corporate purposes, and advancing its strategic business objectives. The infusion of capital is expected to enable the company to further its mission of enhancing cancer care through innovative therapies.

ThinkEquity is acting as the sole book-running manager for this offering, demonstrating confidence in BriaCells potential within the biotechnology sector.

In terms of regulatory compliance, a registration statement on Form S-1 (File No. 333-286670) concerning the securities involved in this offering has been duly filed with the Securities and Exchange Commission (SEC) and became effective on April 24, 2025. It is important to note that this offering is being conducted solely through a prospectus, and copies of the finalized prospectus will be available upon request from ThinkEquity, located at 17 State Street, 41st Floor, New York, New York 10004. Furthermore, the finalized prospectus will also be filed with the SEC and accessible through its official website at

James Whitmore